Seattle Genetics and Agensys, an affiliate of Astellas, have announced the expansion of their 2007 collaboration on antibody-drug conjugates to treat cancer targets. Seattle Genetics gets an upfront payment of US$12 M with the potential to earn up to US$350 M.